This page collects WhisperX intelligence signals tagged #Biotechnology. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
Immix Biopharma shares are rising following a significant vote of confidence from Wall Street. Morgan Stanley has initiated coverage of the clinical-stage biotech company with an Overweight rating, signaling a bullish outlook on its lead CAR-T cell therapy candidate. This move by a major financial institution immediate...
Celcuity has laid out a bold commercial forecast, projecting its lead drug candidate, gedatolisib, could achieve up to $2.5 billion in annual peak revenue. This significant financial target is tied directly to the successful execution of the company's ongoing pivotal clinical trials and its parallel preparations for a ...
Vor Biopharma Inc. has filed a significant 8-K form with the SEC, disclosing multiple material events that signal a period of active corporate and financial maneuvering. The filing, submitted on March 27, 2026, includes entries for a material definitive agreement, unregistered sales of equity securities, a Regulation F...
MaxCyte, Inc. has formally disclosed a significant change in its executive leadership through a filing with the U.S. Securities and Exchange Commission. The 8-K report, filed on March 27, 2026, centers on the departure of a director or certain officer, triggering mandatory disclosure requirements under Item 5.02. This ...
Aurinia Pharmaceuticals is moving to acquire Kezar Life Sciences, a strategic consolidation in the competitive biopharmaceutical landscape. This acquisition signals a deliberate expansion of Aurinia's pipeline and asset portfolio, directly integrating Kezar's research and development efforts into its own operational st...
Champions Oncology, Inc. has formally disclosed significant changes to its executive leadership in a recent SEC filing. The company's 8-K report, filed on March 30, 2026, centers on the departure of directors or certain officers and the appointment of new ones, indicating a notable shift in its corporate governance and...
A new front has opened in the global biotech race, with U.S. venture capital firms now embedding themselves directly inside Chinese research labs. Their goal is to secure stakes in scientific discoveries before they are even published, a strategy that pits them against domestic Chinese VCs who are, in some cases, urgin...
SCYNEXIS, Inc. has filed a significant 8-K form with the SEC, disclosing multiple material events that signal a period of active corporate restructuring and strategic financial moves. The filing, submitted on March 31, 2026, includes entries for a material definitive agreement, unregistered sales of equity securities, ...
Biogen is making a massive $5.6 billion bet on immunology, announcing a deal to acquire Apellis Pharmaceuticals at a price more than double the biotech's recent share value. The upfront cash offer of $41 per share represents a dramatic premium, signaling Biogen's aggressive push to secure commercial-stage assets and re...
Eli Lilly is making a major strategic move into sleep disorders, announcing a $6.3 billion cash acquisition of Centessa Pharmaceuticals. The deal, which values Centessa at a 38% premium over its previous closing price, is centered on securing an experimental drug pipeline designed to combat conditions like narcolepsy. ...
AquaBounty Technologies has filed an amended 8-K form with the SEC, formally disclosing a significant change in control of the company alongside the departure of key directors and officers. This dual filing under Items 5.01 and 5.02 points to a substantial and likely abrupt shift in corporate governance and leadership....
Caribou Biosciences' stock price surged following a critical regulatory milestone. The U.S. Food and Drug Administration (FDA) granted its CB-010 therapy a Regenerative Medicine Advanced Therapy (RMAT) designation. This status is reserved for regenerative medicine therapies, including cell therapies like CAR-T, that de...
Co-Diagnostics is navigating a critical dual-track strategy, aiming to commercialize its tuberculosis test in India by the third quarter of 2026 while simultaneously exploring a potential SPAC transaction for its subsidiary, CoSara. This move signals a pivotal moment for the molecular diagnostics firm as it seeks to un...
Anthropic, the AI safety and research company, has executed a major strategic acquisition, purchasing the stealth-mode biotech AI startup Coefficient Bio in a deal valued at approximately $400 million, according to reports from The Information and journalist Eric Newcomer. The transaction, structured as a stock deal, s...
In a move that signals a significant strategic expansion beyond its core AI research, Anthropic has reportedly acquired the biotech startup Coefficient Bio for approximately $400 million. This acquisition, first reported by Seeking Alpha, represents a substantial financial commitment and a clear pivot for the AI safety...
Vertex Pharmaceuticals has entered a strategic collaboration and licensing agreement with Halozyme Therapeutics, securing access to Halozyme's proprietary ENHANZE® drug delivery technology. The deal centers on Halozyme's Hypercon™ platform, a subcutaneous delivery system designed to enable the rapid administration of l...
A decade after tearing apart the FDA with controversy, exon skipping drugs are re-emerging as a critical, if fraught, lifeline for patients with Duchenne muscular dystrophy. This counterintuitive genetic strategy—fixing a broken gene by breaking it a little more—has taunted desperate families for over twenty years, alw...
Gilead Sciences is making a massive strategic move into a fiercely competitive field, agreeing to acquire the private German biotech firm Tubulis in a deal valued at up to $5 billion. This acquisition is a direct and costly bid to rapidly build a dominant position in a cutting-edge and highly sought-after area of oncol...
The long-standing venture capital playbook for biotech—a formula of U.S. academic science, Big Pharma veterans, and massive capital—is now under direct pressure. The industry is confronting a dual disruption: the rapid, cost-effective rise of innovative research from Chinese scientists and the gravitational pull of art...
BiomX Inc. has filed a dense 8-K form with the SEC, signaling a significant corporate event involving multiple material developments. The filing, submitted on April 10, 2026, encompasses a completion of an asset acquisition, unregistered sales of equity securities, and the entry into new definitive agreements, all of w...